Why the study?
While NOACs have largely replaced warfarin for stroke prevention in atrial fibrillation, challenges remain regarding proper dosing and maintaining adherence.
This review highlights the growing prevalence of atrial fibrillation in Japan and emphasizes that despite the shift from warfarin to NOACs, real-world clinical outcomes remain challenged by inappropriate dosing and adherence issues.
Answers are grounded in this paper and cite their sources.
NOAC dosing and adherence challenges persist in AF stroke prevention; leaves open optimization strategies for clinicians and researchers.
心房細動（atrial fibrillation：AF）は高齢者に多くみられる不整脈疾患であり，日常診療でも遭遇することの多いcommon diseaseであるが，重症脳卒中の原因疾患としても重要である．脳卒中予防には抗凝固療法が有効であるが，その主役は，従来のワルファリンから，その欠点の多くを克服した非ビタミンK拮抗経口抗凝固薬（non-vitamin K antagonist oral anticoagulant：NOAC）に交代し，着実に日常診療において普及してきている．しかし，NOACについても，適正用量の使用やアドヒアランスの維持等の克服すべき課題がある．
No takes yet. Share an insight, caveat, or question.
Masaharu Akao (2019) conducted a review in Atrial Fibrillation. Anticoagulant therapy (Warfarin and NOACs) vs. No anticoagulant therapy was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: